ofloxacin has been researched along with Mycoplasma dispar Infection in 14 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of lethal hepatitis possibly/probably associated with levofloxacin, doxy-cycline, and naproxen in a patient with acute M pneumoniae infection." | 7.75 | Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. ( Andrade, RJ; Carrascosa, MF; Caviedes, JR; Lavín, AC; Lucena, MI; Mones, JC; Rivero, AP; Serrano, VB, 2009) |
| "To assess the safety and efficacy of a ten-day oral course of ofloxacin (400 mg 12 hourly) as compared with erythromycin (400 mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated." | 5.07 | Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin. ( Hooton, TM; Lipsky, BA; Pecoraro, RE; Peugeot, RL, 1991) |
| "We report a case of lethal hepatitis possibly/probably associated with levofloxacin, doxy-cycline, and naproxen in a patient with acute M pneumoniae infection." | 3.75 | Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. ( Andrade, RJ; Carrascosa, MF; Caviedes, JR; Lavín, AC; Lucena, MI; Mones, JC; Rivero, AP; Serrano, VB, 2009) |
| "Ofloxacin was administered orally in 32 cases (200 mg b." | 2.66 | [Treatment of pneumonia caused by Legionella, Mycoplasma, Chlamydiae and Rickettsia using ofloxacin]. ( Beuscart, C; Chidiac, C; Leroy, O; Mouton, Y; Senneville, E; Sivery, B; Vincent du Laurier, M, 1989) |
| "Sparfloxacin was more effective than levofloxacin and ofloxacin in both dosing regimens." | 1.29 | In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ( Irifune, K; Ishida, K; Kaku, M; Mizukane, R; Suyama, N; Takemura, H; Tanaka, H; Tomono, K; Usui, T; Yoshida, R, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 7 (50.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrascosa, MF | 1 |
| Lucena, MI | 1 |
| Andrade, RJ | 1 |
| Caviedes, JR | 1 |
| Lavín, AC | 1 |
| Mones, JC | 1 |
| Rivero, AP | 1 |
| Serrano, VB | 1 |
| Hawkins, S | 1 |
| Rausch, CM | 1 |
| McCanta, AC | 1 |
| Ficko, C | 1 |
| Mellon, G | 1 |
| Andriamanantena, D | 1 |
| Merens, A | 1 |
| Rapp, C | 1 |
| Fukushima, K | 1 |
| Nakatsubo, M | 1 |
| Noda, M | 1 |
| Uenami, T | 1 |
| Hayama, Y | 1 |
| Tsuruta, N | 1 |
| Oniki, S | 1 |
| Saito, Y | 1 |
| Niju, T | 1 |
| Ikeda, T | 1 |
| Duffy, LB | 1 |
| Crabb, DM | 1 |
| Bing, X | 1 |
| Waites, KB | 1 |
| Dunbar, LM | 1 |
| Khashab, MM | 1 |
| Kahn, JB | 1 |
| Zadeikis, N | 1 |
| Xiang, JX | 1 |
| Tennenberg, AM | 1 |
| Kaku, M | 2 |
| Ishida, K | 2 |
| Irifune, K | 1 |
| Mizukane, R | 1 |
| Takemura, H | 1 |
| Yoshida, R | 1 |
| Tanaka, H | 1 |
| Usui, T | 2 |
| Tomono, K | 1 |
| Suyama, N | 1 |
| Gohara, Y | 2 |
| Arai, S | 2 |
| Akashi, A | 2 |
| Kuwano, K | 2 |
| Tseng, CC | 1 |
| Matsubara, S | 1 |
| Matumoto, M | 1 |
| Furudera, T | 1 |
| Nishimoto, M | 1 |
| Yano, T | 1 |
| Oizumi, K | 1 |
| Takeda, K | 1 |
| Yamaguchi, T | 1 |
| Kohno, S | 1 |
| Koga, H | 1 |
| Hara, K | 1 |
| Chidiac, C | 2 |
| Senneville, E | 2 |
| Mouton, Y | 2 |
| Peugeot, RL | 1 |
| Lipsky, BA | 1 |
| Hooton, TM | 1 |
| Pecoraro, RE | 1 |
| Kikuchi, N | 1 |
| Kawashima, T | 1 |
| Onozaki, I | 1 |
| Leroy, O | 1 |
| Beuscart, C | 1 |
| Sivery, B | 1 |
| Vincent du Laurier, M | 1 |
1 review available for ofloxacin and Mycoplasma dispar Infection
| Article | Year |
|---|---|
[Value of quinolones in the treatment of lower respiratory tract infections caused by intracellular organisms, excluding mycobacteria].
Topics: Anti-Infective Agents; Chlamydia Infections; Ciprofloxacin; Enoxacin; Erythromycin; Humans; In Vitro | 1992 |
4 trials available for ofloxacin and Mycoplasma dispar Infection
| Article | Year |
|---|---|
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Topics: Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Inf | 2004 |
Experimental and clinical studies of sparfloxacin in Mycoplasma pneumoniae infection.
Topics: Animals; Anti-Infective Agents; Cricetinae; Fluoroquinolones; Humans; Lung; Male; Mesocricetus; Micr | 1995 |
Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin.
Topics: Adult; Aged; Bronchitis; Chlamydia Infections; Erythromycin; Female; Humans; Legionnaires' Disease; | 1991 |
[Treatment of pneumonia caused by Legionella, Mycoplasma, Chlamydiae and Rickettsia using ofloxacin].
Topics: Adult; Aged; Female; France; Humans; Legionnaires' Disease; Male; Middle Aged; Multicenter Studies a | 1989 |
9 other studies available for ofloxacin and Mycoplasma dispar Infection
| Article | Year |
|---|---|
Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection.
Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Ind | 2009 |
Constrictive pericarditis secondary to infection with Mycoplasma pneumoniae.
Topics: Adolescent; Anti-Bacterial Agents; Cardiac Tamponade; Diagnosis, Differential; Diuretics; Follow-Up | 2011 |
[Acute Mycoplasma pneumonia pancreatitis].
Topics: Abdominal Pain; Acute Disease; Anti-Bacterial Agents; Antibodies, Bacterial; China; DNA, Bacterial; | 2011 |
Anaphylaxis due to intravenous levofloxacin with tolerance to garenoxacin.
Topics: Adult; Anaphylaxis; Anti-Bacterial Agents; Cross Reactions; Drug Hypersensitivity; Fluoroquinolones; | 2012 |
Bactericidal activity of levofloxacin against Mycoplasma pneumoniae.
Topics: Anti-Bacterial Agents; Humans; Kinetics; Levofloxacin; Microbial Sensitivity Tests; Mycoplasma pneum | 2003 |
In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
Topics: Animals; Anti-Infective Agents; Cricetinae; Fluoroquinolones; Humans; Levofloxacin; Lung; Mesocricet | 1994 |
In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Cricetinae; Drug Resistance, Mi | 1993 |
Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Ciprofloxacin; Cricetinae; Female; Fluoroquin | 1993 |
[Clinical evaluations of ofloxacin in the treatment of Mycoplasma pneumoniae pneumonia in adults].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Male; Middle Aged; Ofloxacin; Pneumonia, My | 1990 |